Dr. Ben Cons has more than 30 years’ experience in pharmaceutical R&D and commercialization in the biotech, pharmaceutical and financing sectors. He is a prominent leader in global healthcare and technology, and has 20 years of experience with the NYSE-listed pharmaceutical services company IQVIA where he was SVP for corporate development and its associated investment fund NovaQuest. Currently, Dr. Cons is a Special Partner at the private equity fund Vitruvian, Chairman of Charnwood Molecular and Chairman of Castor EDC. In addition Dr. Cons is a NED of Talking Medicines, Fluidic Analytics and Board Advisor to Azadyne.
Dr. Cons has a PhD in molecular pharmacology from Southampton University.
Dr. Cons' early career included working in respiratory drug development, marketing and business development at Glaxo and diagnostic imaging drug development at Schering.